StockData
Rallybio Corp logo

Rallybio Corp (RLYB) stock

RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.47−0.05 (-0.32%)

Close on Nov 20, 2026Market cap $83.29MP/E 3.4Yield –

Rallybio net income

Net income is the profit left for shareholders after every expense, interest and tax.

Rallybio's net income for the twelve months ending Sep 30, 2026 was $26.81M. For fiscal 2025 it was -$8.98M. The highest annual figure on record is -$8.98M in fiscal 2025.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$8.98M–
FY2024Dec 31, 2024-$57.78M–
FY2023Dec 31, 2023-$74.56M–
FY2022Dec 31, 2022-$66.65M–
FY2021Dec 31, 2021-$47.01M–
FY2020Dec 31, 2020-$26.45M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$2.73M-117.0%
Q2 FY2026Jun 30, 2026$43.67M–
Q1 FY2026Mar 31, 2026-$8.28M–
Q4 FY2025Dec 31, 2025-$5.85M–
Q3 FY2025Sep 30, 2025$16.02M–
Q2 FY2025Jun 30, 2025-$9.70M–
Q1 FY2025Mar 31, 2025-$9.44M–
Q4 FY2024Dec 31, 2024-$11.04M–
Q3 FY2024Sep 30, 2024-$11.47M–
Q2 FY2024Jun 30, 2024-$16.24M–
Q1 FY2024Mar 31, 2024-$19.03M–
Q4 FY2023Dec 31, 2023-$20.24M–
Q3 FY2023Sep 30, 2023-$18.37M–
Q2 FY2023Jun 30, 2023-$18.63M–
Q1 FY2023Mar 31, 2023-$17.32M–
Q4 FY2022Dec 31, 2022-$16.20M–
Q3 FY2022Sep 30, 2022-$18.37M–
Q2 FY2022Jun 30, 2022-$17.58M–
Q1 FY2022Mar 31, 2022-$14.50M–
Q4 FY2021Dec 31, 2021-$12.42M–
Q3 FY2021Sep 30, 2021-$10.20M–
Q2 FY2021Jun 30, 2021-$11.13M–
Q1 FY2021Mar 31, 2021-$13.28M–
Q4 FY2020Dec 31, 2020-$10.52M–
Q3 FY2020Sep 30, 2020-$7.16M–
Q2 FY2020Jun 30, 2020-$4.89M–

More Rallybio figures

See a number that looks wrong?